JP2010538680A - 肺疾患に対する薬剤開発のための新規経路の同定 - Google Patents

肺疾患に対する薬剤開発のための新規経路の同定 Download PDF

Info

Publication number
JP2010538680A
JP2010538680A JP2010526034A JP2010526034A JP2010538680A JP 2010538680 A JP2010538680 A JP 2010538680A JP 2010526034 A JP2010526034 A JP 2010526034A JP 2010526034 A JP2010526034 A JP 2010526034A JP 2010538680 A JP2010538680 A JP 2010538680A
Authority
JP
Japan
Prior art keywords
pi3k
pathway
activation
individual
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010526034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010538680A5 (enExample
Inventor
ジェローム エス． ブローディー，
アブラム スピラ，
アダム ガスタフソン，
アンドレア ビルド，
Original Assignee
ザ トラスティーズ オブ ボストン ユニバーシティー
ザ ユニバーシティ オブ ユタ リサーチ ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ トラスティーズ オブ ボストン ユニバーシティー, ザ ユニバーシティ オブ ユタ リサーチ ファウンデーション filed Critical ザ トラスティーズ オブ ボストン ユニバーシティー
Publication of JP2010538680A publication Critical patent/JP2010538680A/ja
Publication of JP2010538680A5 publication Critical patent/JP2010538680A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2010526034A 2007-09-19 2008-09-19 肺疾患に対する薬剤開発のための新規経路の同定 Pending JP2010538680A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99464307P 2007-09-19 2007-09-19
PCT/US2008/077136 WO2009039457A1 (en) 2007-09-19 2008-09-19 Identification of novel pathways for drug development for lung disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014155833A Division JP2014204737A (ja) 2007-09-19 2014-07-31 肺疾患に対する薬剤開発のための新規経路の同定

Publications (2)

Publication Number Publication Date
JP2010538680A true JP2010538680A (ja) 2010-12-16
JP2010538680A5 JP2010538680A5 (enExample) 2012-10-11

Family

ID=40468411

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010526034A Pending JP2010538680A (ja) 2007-09-19 2008-09-19 肺疾患に対する薬剤開発のための新規経路の同定
JP2014155833A Pending JP2014204737A (ja) 2007-09-19 2014-07-31 肺疾患に対する薬剤開発のための新規経路の同定

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014155833A Pending JP2014204737A (ja) 2007-09-19 2014-07-31 肺疾患に対する薬剤開発のための新規経路の同定

Country Status (7)

Country Link
US (3) US20090186951A1 (enExample)
EP (1) EP2193211A4 (enExample)
JP (2) JP2010538680A (enExample)
CN (1) CN101990577A (enExample)
AU (1) AU2008302076B2 (enExample)
CA (1) CA2700200A1 (enExample)
WO (1) WO2009039457A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148650A1 (en) * 2003-11-12 2007-06-28 Trustees Of Boston University Isolation of nucleic acid from mouth epithelial cells
JP2008537120A (ja) * 2005-04-14 2008-09-11 ザ トラスティーズ オブ ボストン ユニバーシティ 分類予測を使用した肺障害についての診断
JP2009529329A (ja) 2006-03-09 2009-08-20 トラスティーズ オブ ボストン ユニバーシティ 鼻腔上皮細胞の遺伝子発現プロファイルを用いた、肺疾患のための診断および予後診断の方法
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
CN101990577A (zh) 2007-09-19 2011-03-23 波士顿大学理事会 鉴定肺病药物开发的新途径
US20100055689A1 (en) * 2008-03-28 2010-03-04 Avrum Spira Multifactorial methods for detecting lung disorders
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
UY32317A (es) 2008-12-12 2010-07-30 Boehringer Ingelheim Int Anticuerpos anti-igf
EP3360978A3 (en) 2009-05-07 2018-09-26 Veracyte, Inc. Methods for diagnosis of thyroid conditions
US9895321B2 (en) * 2010-04-23 2018-02-20 Aktiv-Dry Llc Vaccines, methods of administering vaccines, methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration
WO2012130720A2 (en) * 2011-03-28 2012-10-04 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh PREDICTION OF RESPONSIVENESS TO PIK3/mTOR INHIBITORS
JP5841234B2 (ja) 2011-03-31 2016-01-13 ザ プロクター アンド ギャンブルカンパニー フケ／脂漏性皮膚炎の治療に有効な皮膚活性剤を特定及び評価するためのシステム、モデル、及び方法
WO2013177060A2 (en) * 2012-05-20 2013-11-28 Trustees Of Boston University Methods and systems for monitoring, diagnosing, and treating chronic obstructive polmonary disease
MX2014014898A (es) 2012-06-06 2015-03-04 Procter & Gamble Sistemas y metodos de identificacion de agentes cosmeticos para composiciones para el cuidado del cabello/cuero cabelludo.
WO2013190092A1 (en) 2012-06-21 2013-12-27 Philip Morris Products S.A. Gene signatures for copd diagnosis
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
EP2968988A4 (en) 2013-03-14 2016-11-16 Allegro Diagnostics Corp METHOD FOR EVALUATING A COPD STATUS
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP3916110A1 (en) 2014-07-14 2021-12-01 Veracyte, Inc. Methods for evaluating lung cancer status
CN114606309A (zh) 2014-11-05 2022-06-10 威拉赛特公司 使用机器学习和高维转录数据的诊断系统和方法
US20190292600A1 (en) 2016-05-12 2019-09-26 Trustees Of Boston University Nasal epithelium gene expression signature and classifier for the prediction of lung cancer
WO2018009915A1 (en) 2016-07-08 2018-01-11 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005294A1 (en) * 2002-02-25 2004-01-08 Ho-Young Lee IGFBP-3 in the diagnosis and treatment of cancer

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3640268A (en) * 1965-10-23 1972-02-08 Hugh J Davis Method and device for biopsy specimen collecting and handling
US4641662A (en) * 1984-09-28 1987-02-10 Jaicks John R Endocervical curette system
US4800896A (en) * 1985-11-08 1989-01-31 Jalowayski Alfredo A Cell sample collector probe
US5726060A (en) 1991-09-17 1998-03-10 Bridges; Michael Anthony Method for culturing mammalian respiratory epithelial cells
US5422273A (en) * 1993-03-23 1995-06-06 Baal Medical Products, Inc. Cell collection apparatus
US5876978A (en) 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5477863A (en) * 1993-04-14 1995-12-26 Grant; Michael A. Collection kit with a sample collector
US5440942A (en) * 1994-02-02 1995-08-15 Hubbard; Stephen H. Biological sample collecting and holding device
US5795782A (en) 1995-03-17 1998-08-18 President & Fellows Of Harvard College Characterization of individual polymer molecules based on monomer-interface interactions
US6085907A (en) * 1998-05-08 2000-07-11 Institute Of Legal Medicine, University Of Bern Foldable cardboard box for contact-free drying and long-term storage of biological evidence recovered on cotton swabs and forensic evidence collection kit including same
CA2328138A1 (en) 1998-05-21 1999-11-25 Diadexus Llc A novel method of diagnosing, monitoring, and staging lung cancer
US6204375B1 (en) 1998-07-31 2001-03-20 Ambion, Inc. Methods and reagents for preserving RNA in cell and tissue samples
US20040241728A1 (en) * 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of lung disease related gene transcripts in blood
US6746846B1 (en) * 1999-06-30 2004-06-08 Corixa Corporation Methods for diagnosing lung cancer
CN1379641A (zh) 1999-10-18 2002-11-13 丹尼斯·马歇尔－弗雷泽 取样装置
US6383804B1 (en) 2000-07-13 2002-05-07 International Bioproducts, Inc. Sampling device with snap-off head and method of use
AU2001281136A1 (en) 2000-08-04 2002-02-18 Board Of Regents, The University Of Texas System Detection and diagnosis of smoking related cancers
EP1346043A2 (en) 2000-11-20 2003-09-24 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
WO2002044331A2 (en) 2000-11-29 2002-06-06 Cangen International Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer
US6972181B2 (en) 2001-01-12 2005-12-06 Mount Sinai School Of Medicine Of New York University Differential diagnosis of cancer and other conditions based on expression of p63
WO2003040325A2 (en) 2001-02-01 2003-05-15 Curagen Corporation Novel proteins and nucleic acids encoding same
KR20030094281A (ko) * 2001-03-12 2003-12-11 모노젠, 인크. 세포에 기초한 질병상태의 검출 및 질병상태의 구별
US20040197785A1 (en) * 2001-03-14 2004-10-07 Willey James C. Method for quantitative measurement of gene expression for indentifying individuals at risk for bronchogenic carcinoma
CA2444691A1 (en) 2001-04-18 2002-10-31 Protein Design Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
JP2005503145A (ja) 2001-08-16 2005-02-03 ザ ユナイテッド ステイツ オブ アメリカ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 非小細胞肺癌の分子特性
AU2002343443A1 (en) * 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
US8722331B2 (en) * 2002-03-28 2014-05-13 University Of Toledo Method for selecting a treatment for non-small cell lung cancer using gene expression profiles
DE10219117C1 (de) 2002-04-29 2003-10-30 Adnagen Ag Verfahren zur Stabilisierung von RNS und Verwendungen von Stabilisierungspuffern
WO2004005891A2 (en) 2002-07-10 2004-01-15 The Regents Of The University Of Michigan Expression profile of lung cancer
WO2004029055A1 (en) * 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
US20040241725A1 (en) * 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
WO2004091511A2 (en) 2003-04-10 2004-10-28 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer
WO2004111197A2 (en) 2003-06-10 2004-12-23 Trustees Of Boston University Gene expression signatures, methods and compositions for diagnosing disorders of the lung
EP2316973A1 (en) * 2003-06-10 2011-05-04 The Trustees Of Boston University Detection methods for disorders of the lung
US20070148650A1 (en) 2003-11-12 2007-06-28 Trustees Of Boston University Isolation of nucleic acid from mouth epithelial cells
AU2005220746A1 (en) * 2004-03-05 2005-09-22 Medical College Of Ohio Methods and compositions for assessing nucleic acids and alleles
WO2006056080A1 (en) 2004-11-29 2006-06-01 Diagnocure Inc. Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
EP2281841A3 (en) * 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomarkers for pre-selection of patients for anti-IGF1R therapy
US7862995B2 (en) * 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
WO2006079087A2 (en) * 2005-01-21 2006-07-27 Gene Express, Inc. Compositions and methods of use of standardized mixtures
JP2008537120A (ja) 2005-04-14 2008-09-11 ザ トラスティーズ オブ ボストン ユニバーシティ 分類予測を使用した肺障害についての診断
AU2006287191A1 (en) * 2005-09-02 2007-03-08 The University Of Toledo Methods and compositions for identifying biomarkers useful in diagnosis and/or treatment of biological states
JP2009529329A (ja) 2006-03-09 2009-08-20 トラスティーズ オブ ボストン ユニバーシティ 鼻腔上皮細胞の遺伝子発現プロファイルを用いた、肺疾患のための診断および予後診断の方法
US7832459B2 (en) 2007-08-30 2010-11-16 Phillips Plastics Corporation Methods, tools, and products for molded ordered porous structures
CN101990577A (zh) 2007-09-19 2011-03-23 波士顿大学理事会 鉴定肺病药物开发的新途径
US20090246779A1 (en) 2008-02-15 2009-10-01 University Of Washington Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-cgh
US20100055689A1 (en) * 2008-03-28 2010-03-04 Avrum Spira Multifactorial methods for detecting lung disorders
US9068974B2 (en) 2008-11-08 2015-06-30 The Wistar Institute Of Anatomy And Biology Biomarkers in peripheral blood mononuclear cells for diagnosing or detecting lung cancers
EP2775300A3 (en) 2009-08-28 2015-04-01 Asuragen, INC. miRNA Biomarkers of Lung Disease
US20130303826A1 (en) 2011-01-11 2013-11-14 University Health Network Prognostic signature for oral squamous cell carcinoma
US20120288860A1 (en) 2011-05-12 2012-11-15 George Mason University Differential gene expression for detecting and/or differentiating lung disease
WO2013033640A1 (en) 2011-09-01 2013-03-07 Allegro Diagnostics Corp. Methods and compositions for detecting cancer based on mirna expression profiles
WO2013049152A2 (en) 2011-09-26 2013-04-04 Allegro Diagnostics Corp. Methods for evaluating lung cancer status
CA2865335A1 (en) 2012-03-09 2013-09-12 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
WO2013163568A2 (en) 2012-04-26 2013-10-31 Allegro Diagnostics Corp. Methods for evaluating lung cancer status
WO2013177060A2 (en) 2012-05-20 2013-11-28 Trustees Of Boston University Methods and systems for monitoring, diagnosing, and treating chronic obstructive polmonary disease
EP2968988A4 (en) 2013-03-14 2016-11-16 Allegro Diagnostics Corp METHOD FOR EVALUATING A COPD STATUS
EP4219761A1 (en) 2013-03-15 2023-08-02 Veracyte, Inc. Biomarkers for diagnosis of lung diseases and methods of use thereof
WO2018048960A1 (en) 2016-09-07 2018-03-15 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
EP3916110A1 (en) 2014-07-14 2021-12-01 Veracyte, Inc. Methods for evaluating lung cancer status
US20190292600A1 (en) 2016-05-12 2019-09-26 Trustees Of Boston University Nasal epithelium gene expression signature and classifier for the prediction of lung cancer
WO2018009915A1 (en) 2016-07-08 2018-01-11 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005294A1 (en) * 2002-02-25 2004-01-08 Ho-Young Lee IGFBP-3 in the diagnosis and treatment of cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN5010012818; Ｃｈｉｎｅｓｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃａｎｃｅｒ Ｖ２５　Ｎ１０, 2006, Ｐ１２３８-１２４２ *
JPN5010012819; ［ＯＮＬＩＮＥ］ , 20070611 *
JPN5011008677; ＳＰＩＲＡ　ＡＶＲＵＭ: 'ＡＩＲＷＡＹ　ＥＰＩＴＨＥＬＩＡＬ　ＧＥＮＥ　ＥＸＰＲＥＳＳＩＯＮ　ＩＮ　ＴＨＥ　ＤＩＡＧＮＯＳＴＩＣ　ＥＶＡＬＵＡＴＩＯＮ　ＯＦ　ＳＭＯＫＥＲＳ　ＷＩＴＨ　ＳＵＳＰＥＣＴ　ＬＵＮＧ　ＣＡＮＣＥＲ' ＮＡＴＵＲＥ　ＭＥＤＩＣＩＮＥ Ｖ１３　Ｎ３, 200703, Ｐ３６１-３６６ *
JPN6013038078; Ｃｒｉｔｉｃａｌ　Ｒｅｖｉｅｗｓ　ｉｎ　Ｏｎｃｏｌｏｇｙ／Ｈｅｍａｔｏｌｏｇｙ Ｖｏｌ．６３, 2007, ｐ．１７２-１８２ *
JPN6013038082; Ｐｈａｒｍａｃｏｌｏｇｉｃａｌ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．５５, 2007, ｐ．５４５-５５９ *
JPN6013038085; Ｃａｎｃｅｒ　Ｅｐｉｄｅｍｉｏｌ　Ｂｉｏｍａｒｋｅｒｓ　Ｐｒｅｖ Ｖｏｌ．１５, 2006, ｐ．１５２６-１５３１ *

Also Published As

Publication number Publication date
US20150232945A1 (en) 2015-08-20
WO2009039457A1 (en) 2009-03-26
EP2193211A1 (en) 2010-06-09
EP2193211A4 (en) 2010-12-08
AU2008302076B2 (en) 2015-06-11
AU2008302076A1 (en) 2009-03-26
US20090186951A1 (en) 2009-07-23
US10570454B2 (en) 2020-02-25
CA2700200A1 (en) 2009-03-26
JP2014204737A (ja) 2014-10-30
CN101990577A (zh) 2011-03-23
US20200232045A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
JP2014204737A (ja) 肺疾患に対する薬剤開発のための新規経路の同定
Rotunno et al. Parity-related molecular signatures and breast cancer subtypes by estrogen receptor status
JP2008537120A (ja) 分類予測を使用した肺障害についての診断
WO2018009915A1 (en) Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
EP3028047B1 (en) Compositions and methods for identifying a risk of cancer in a subject
US20150275307A1 (en) Compositions and methods for detecting sessile serrated adenomas/polyps
US8455196B2 (en) Biomarker for identifying subgroup of early-stage lung adenocarcinoma patients
US12221655B2 (en) Pre-surgical risk stratification based on PDE4D7 and DHX9 expression
Zhao et al. HEG1 promotes gastric cancer progression by stabilizing AKT1 and is functionally regulated by the deubiquitinase USP48
Zhai et al. Interactions between environmental factors and polymorphisms in angiogenesis pathway genes in esophageal adenocarcinoma risk: A case‐only study
US20230019818A1 (en) Methods of detecting and treating hpv-positive head and neck squamous cell carcinoma
Huang et al. PRDM1: a useful indicator of differentiation and prognosis in esophageal squamous cell carcinoma
WO2023002725A1 (en) Biomarkers for a therapy comprising an angiogenesis inhibitor
Elkahwagy et al. Dysregulated long non coding RNA as biomarkers for diagnosis of Mesothelioma: A Systematic Review
Gingras Age at Diagnosis and Lung Cancer Presentation
Saini et al. Matrix Metalloproteinase-1 (MMP-1) as a Biomarker to Predict Disease Progression and Survival Outcomes in Oral Cancer
KR20240053637A (ko) 개선된 암 진단 및 치료법 선택을 위한 차세대 시퀀싱 및 인공 지능-기반 접근법
Dube Comparison of Xpert® Breast cancer STRAT4 assay and immunohistochemistry for the evaluation of breast cancer biomarkers in South African patients
CN116411072A (zh) 一种肢端型黑色素瘤诊疗标志物组合及其应用
Sakr Hürthle Cell Lesions of the Thyroid
McLean Evaluating the Utility of Protein Biomarker, S100A7, and Diagnostic Test, Straticyte, in Predicting the Progression of Oral Dysplasia
van der Logt et al. ESP Abstracts 2013

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131024

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140827

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140919